Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 4
2016 2
2017 10
2018 14
2019 30
2020 45
2021 59
2022 92
2023 83
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.
Darolutamide was also associated with consistent benefits with respect to the secondary end points and prespecified subgroups. ...CONCLUSIONS: In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer wit …
Darolutamide was also associated with consistent benefits with respect to the secondary end points and prespecified subgroups. ...CON …
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
BACKGROUND: Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. ...CONCLUSIONS: Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free survival was significantly lon …
BACKGROUND: Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostat …
Darolutamide.
[No authors listed] [No authors listed] 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37023244 Free Books & Documents. Review.
Darolutamide is a third generation, oral nonsteroidal antiandrogen used to treat nonmetastatic castration-resistant prostate cancer. Darolutamide is associated with a low rate of serum enzyme elevation during therapy, but has not been linked to cases of clinically a …
Darolutamide is a third generation, oral nonsteroidal antiandrogen used to treat nonmetastatic castration-resistant prostate cancer. …
Darolutamide: First Approval.
Markham A, Duggan S. Markham A, et al. Drugs. 2019 Nov;79(16):1813-1818. doi: 10.1007/s40265-019-01212-y. Drugs. 2019. PMID: 31605368 Review.
Darolutamide (NUBEQA) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a treatment for prostate cancer. ...This article summarizes the milestones in the development of darolutamide leading to this first appr …
Darolutamide (NUBEQA) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a t …
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Hussain M, et al. J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16. J Clin Oncol. 2023. PMID: 36795843 Clinical Trial.
METHODS: Patients with metastatic hormone-sensitive prostate cancer were randomly assigned to darolutamide or placebo plus androgen-deprivation therapy and docetaxel. ...Darolutamide improved clinically relevant secondary end points of time to castration-resistant p …
METHODS: Patients with metastatic hormone-sensitive prostate cancer were randomly assigned to darolutamide or placebo plus androgen-d …
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, Denner K, Bairlein M, von Bühler CJ, Wilkinson G, Gieschen H. Zurth C, et al. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. doi: 10.1007/s13318-019-00577-5. Eur J Drug Metab Pharmacokinet. 2019. PMID: 31571146 Free PMC article. Clinical Trial.
In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity. ...Co-administration of darolutamide with CYP3A4/P-gp substrates showed no effect or only minor effects. ...
In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity. ...Co-administration of darolutamide with …
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
Lee A. Lee A. Target Oncol. 2023 Sep;18(5):793-800. doi: 10.1007/s11523-023-00984-4. Epub 2023 Aug 5. Target Oncol. 2023. PMID: 37542594 Free PMC article. Review.
Treatment with darolutamide plus ADT and docetaxel was associated with a manageable tolerability profile. ...Darolutamide plus ADT and docetaxel had a manageable tolerability profile and the adverse events reported with darolutamide plus ADT and docetaxel wer …
Treatment with darolutamide plus ADT and docetaxel was associated with a manageable tolerability profile. ...Darolutamide plus …
Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
Palmieri VE, Roviello G, D'Angelo A, Casadei C, De Giorgi U, Giorgione R. Palmieri VE, et al. Expert Rev Clin Pharmacol. 2021 May;14(5):535-544. doi: 10.1080/17512433.2021.1901580. Epub 2021 Mar 21. Expert Rev Clin Pharmacol. 2021. PMID: 33685318 Review.
In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This manuscript aims to profile darolutamide, its clinical development, pharmacologic properties, efficacy and safety. ...While the clinica …
In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This m …
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
BACKGROUND: Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. ...Overall survival at 3 years was 83% (95% confidence interval [CI], 80 to 86) in the darolutamide …
BACKGROUND: Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, …
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
Cattrini C, Caffo O, De Giorgi U, Mennitto A, Gennari A, Olmos D, Castro E. Cattrini C, et al. Cancers (Basel). 2022 Mar 31;14(7):1792. doi: 10.3390/cancers14071792. Cancers (Basel). 2022. PMID: 35406564 Free PMC article. Review.
The SPARTAN, ARAMIS and PROSPER trials showed that apalutamide, darolutamide and enzalutamide, respectively, prolong metastasis-free survival (MFS) and overall survival (OS) of nmCRPC patients with a short PSA doubling time, and these antiandrogens have been recently intro …
The SPARTAN, ARAMIS and PROSPER trials showed that apalutamide, darolutamide and enzalutamide, respectively, prolong metastasis-free …
327 results